Peritoneal mesothelioma is a rare and aggressive malignancy [ of the peritoneum ] that often presents with non-specific abdominal symptoms such as ascites, leading to delayed diagnosis and treatment. It poses significant diagnostic challenges, especially in the absence of classical risk factors like asbestos exposure. We report the case of a … [Read more...]
The global burden of mesothelioma and its association with asbestos bans, 1990–2021: a population-based study
Background: Mesothelioma, as a lethal consequence of asbestos exposure, poses a significant threat to high-risk populations. The Global Burden of Disease (GBD) 2021 update provides an opportunity to examine current mesothelioma epidemiology and assess whether asbestos bans have effectively reduced mesothelioma incidence over a longer time span … [Read more...]
Diagnostic Differentiation Between Two Rare Entities—Metastatic Peritoneal Mesothelioma With Duodenal Involvement and Duodenal Synovial Sarcoma: A Case Report
Abstract: This case report highlights the diagnostic challenges in distinguishing between metastatic peritoneal mesothelioma with duodenal involvement and synovial sarcoma of the duodenum, two rare and complex entities. A 59-year-old woman presented with nonspecific abdominal symptoms, and imaging revealed a heterogeneous lesion between the right … [Read more...]
A Review of Job Assignments and Asbestos Workplace Exposure Measurements for TAWP Mesothelioma Deaths Through 2011
ABSTRACT Introduction: Asbestos workers have a higher risk of developing mesothelioma; however, few studies have looked at specific jobs and job locations within asbestos factories. The purpose of this study was to investigate asbestos exposure in different job locations of the Tyler, Texas asbestos plant to determine if there was a relationship … [Read more...]
Recent Advances in Mesothelioma Treatment: Immunotherapy, Advanced Cell Therapy, and Other Innovative Therapeutic Modalities
Mesothelioma is a malignant condition arising from the pleura and peritoneum that is closely related to asbestos exposure. Due to the prolonged time needed for one to fully develop mesothelioma, difficulty in diagnosing this condition early, its quick progression once manifested, and the limited treatment options, the prognosis for this condition … [Read more...]
Treatment of Pleural Mesothelioma: ASCO Guideline Update
Since the initial [American Society of Clinical Oncologists (ASCO)] clinical practice guideline on the treatment of malignant pleural mesothelioma (PM) was published in 2018 considerable progress has been made which has changed not only the management but even the name of this disease. This guideline update focuses on four key areas: the role of … [Read more...]
The presence of pleural effusion is an independent prognostic factor in patients with malignant pleural mesothelioma
Abstract: Malignant pleural mesothelioma (MPM) is a rare form of thoracic malignancy with a poor prognosis. Pleural effusion (PE) occurs in the majority of patients with MPM; however, its impact on MPM outcomes remains controversial. We searched for eligible patients from the Surveillance, Epidemiology, and End Results (SEER) database, and … [Read more...]
Diffuse Pleural Mesothelioma: A Challenge in Early Diagnosis
Abstract: We present the clinical case of a 58-year-old female patient, a smoker with occupational exposure to respiratory toxins, who was admitted to our clinic following evaluation in an emergency department, where she was diagnosed with a moderate right pleural effusion. Upon admission, the patient exhibited respiratory symptoms, including … [Read more...]
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline
Introduction The purpose of this guideline is to provide recommendations for the management of patients with malignant pleural mesothelioma (MPM), an aggressive tumor with a poor prognosis. In the United States, about 3,000 new cases are diagnosed each year. The median overall survival of patients with advanced surgically unresectable disease is … [Read more...]
FDA Approves Pembrolizumab Plus Chemo for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
The FDA has approved [ Keytruda (pembrolizumab) ] plus pemetrexed and platinum chemotherapy in the frontline treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. Data from the phase 2/3 KEYNOTE-483 study (NCT02784171) showed that [ Keytruda (pembrolizumab) ] plus chemotherapy (n = 222) significantly … [Read more...]
- 1
- 2
- 3
- …
- 7
- Next Page »